Bevacizumab, a VEGFA-specific antibody, induced an objective response rate in 16% of patients with recurrent ovarian cancer and stabilized disease for 5.5 months in 50% of patients [33], while improved response rates have been observed in platinum-resistant disease when it was used in combination with cytotoxic chemotherapy [34]. The gene discussed is VEGFA; the disease is ovarian carcinoma.